Distinguished in Myeloproliferative Neoplasms (MPN)

Dr. Richard T. Silver

Psychiatry
1425 S Main St, 
Walnut Creek, CA 
Distinguished in Myeloproliferative Neoplasms (MPN)
1425 S Main St, 
Walnut Creek, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Silver is a Psychiatrist in Walnut Creek, California. Dr. Silver is rated as a Distinguished provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Myeloproliferative Neoplasms (MPN), Systemic Sclerosis (SSc), and Pulmonary Fibrosis.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles and participated in 1 clinical trial in the study of Myeloproliferative Neoplasms (MPN).

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO

Locations

1425 S Main St, Walnut Creek, CA 94596

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Enrollment Status: Terminated
Publish Date: February 13, 2024
Intervention Type: Biological
Study Drugs: Haplo-identical cells, Umbilical cord blood unit
Study Phase: Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML
Enrollment Status: Completed
Publish Date: February 28, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Molecular Biology of Familial Myeloproliferative Disorders
Molecular Biology of Familial Myeloproliferative Disorders
Enrollment Status: Completed
Publish Date: September 05, 2017
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

97 Total Publications

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
Journal: Leukemia
Published: May 29, 2025
Similar Doctors
Experienced in Myeloproliferative Neoplasms (MPN)
Dr. Dheeraj Kodali
Hematology Oncology | Hematology | Oncology
Experienced in Myeloproliferative Neoplasms (MPN)
Dr. Dheeraj Kodali
Hematology Oncology | Hematology | Oncology

Stockton Hematology Oncology Medical Group Inc

2626 N California St, Suite B, 
Stockton, CA 
 (42.3 miles away)
209-466-2626
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dheeraj Kodali is a Hematologist Oncology specialist and a Hematologist in Stockton, California. Dr. Kodali is rated as an Advanced provider by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Pleuropulmonary Blastoma, Acute Mountain Sickness, Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia. Dr. Kodali is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Silver's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile